SB 5455
SignedSenate
Cancer research endowment
Concerning the administration of the Andy Hill cancer research endowment.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill strengthens and expands Washington’s Andy Hill Cancer Research Endowment, which funds cancer research, prevention, and care through grants to institutions and businesses in the state. It updates governance, adds new grant evaluation criteria, and formalizes a state matching fund supported by tobacco taxes. The endowment is designed to leverage private investment and ensure accountability through independent oversight and public reporting.
- Creates and expands the Andy Hill Cancer Research Endowment and its governing board, increasing board membership to 13 members with diverse representation from academia, health care, advocacy, business, and the public.
- Requires grants to be awarded only after review and recommendation by an independent scientific advisory committee, ensuring peer review of proposals.
- Adds new criteria for grant evaluation, including cultural and linguistic accessibility, geographic diversity, commercialization potential, and engagement of underrepresented communities in clinical trials.
- Establishes the Andy Hill Cancer Research Fund as a private account outside the state treasury, funded by private and public contributions, with state matching funds up to $10 million annually from tobacco taxes.
- Requires the program administrator to manage the fund for maximum investment return and to ensure grantees prioritize purchasing from Washington-based suppliers.
- Mandates annual public reporting on grant activity, research outcomes, and program impact, plus independent performance audits at least every three years.
Who is affected
- Research and health care institutions — Nonprofit organizations, universities, hospitals, and clinics in Washington that may apply for grants to conduct cancer research, prevention, or care programs.
- Commercial life sciences businesses — For-profit life sciences and health care companies in Washington that may receive grants to develop and commercialize cancer-related products or services.
- Cancer patients and families — Cancer patients and their families who may benefit from improved research, prevention, and care options funded by the endowment.
- State taxpayers and tobacco consumers — State taxpayers and tobacco product consumers, as the endowment is partially funded by tobacco-related taxes and requires state matching funds.
- Private donors and foundations — Private donors and foundations that contribute funds to the endowment and may have a voice through board nominations.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Mandating culturally and linguistically accessible recruitment, consent, and outreach for underrepresented communities in clinical trials is a significant step toward reducing racial/ethnic disparities in cancer care access and outcomes—directly benefiting historically excluded patients and communities.
HealthcarePeopleRef: RCW 43.348.040(3)(i), (j), (k), (l)The state matching fund (up to $10M/year) is triggered only when equal or greater private contributions are committed, effectively leveraging state tobacco tax revenues to attract substantial private investment—increasing total funding for cancer research without increasing net state costs.
FinancialPeopleRef: RCW 43.348.060(1)(b)The requirement to consider potential for stimulating life science and biomedical employment in Washington, combined with geographic diversity in grant allocation, supports job growth across the state—not just in the Puget Sound region—benefiting workers in mid-sized and rural communities.
Business & EmploymentPeopleRef: RCW 43.348.040(3)(e), (f)Mandating independent scientific review (via the advisory committee), annual public reporting, and conflict-of-interest policies strengthens integrity and transparency in publicly funded research—enhancing public trust and reducing opportunities for misuse of funds.
Public SafetyPeopleRef: RCW 43.348.040(2), (5), (8)Requiring grants to improve health outcomes *and* lower overall health care costs—through substitution, breakthrough treatments, or cost-saving innovations—aligns research incentives with value-based care goals, potentially reducing long-term costs for patients and public health programs like Medicaid.
HealthcarePeopleRef: RCW 43.348.040(3)(b)
Potential Concerns (5)
The creation of a separate private account outside the state treasury for the Andy Hill Cancer Research Fund reduces transparency and accountability in state financial management, as these funds are not subject to standard state budget oversight, audit, or constitutional spending limits—potentially weakening accountability for public funds used in matching roles.
Public SafetyPeopleRef: RCW 43.348.060(1)(b)While the bill mandates grantees prioritize purchasing from Washington suppliers, it does not enforce this requirement or define “reasonably possible,” leaving implementation to grantees’ discretion—likely benefiting large institutions with existing supply chains over small in-state vendors and potentially diluting local economic benefits.
Business & EmploymentPeopleRef: RCW 43.348.060(1)(c)The requirement to include underrepresented communities in clinical trials is well-intentioned, but without dedicated funding for outreach, translation, or infrastructure support, compliance may fall to already overburdened community clinics and safety-net providers—increasing their operational burden without additional reimbursement.
HealthcareLean peopleRef: RCW 43.348.040(3)(l)The bill requires annual public reporting and triennial independent audits, but does not mandate standardized metrics or public dashboards—limiting the ability of local governments and community organizations to track outcomes or hold grantees accountable for geographic equity.
Local GovernmentLean peopleRef: RCW 43.348.060(1)(e)The emphasis on commercialization potential and revenue recapture may prioritize high-return, marketable research over high-need but less profitable areas (e.g., rare cancers, palliative care), skewing research priorities toward profitable therapeutics and away from public health needs.
Business & EmploymentLean peopleRef: RCW 43.348.040(3)(g)
Who Is Most Affected
Cancer patients and families—especially those from low-income, rural, or racially/ethnically diverse backgrounds—will benefit most from improved access to culturally competent clinical trials and potentially lower-cost, high-impact treatments. However, those without internet access or transportation may still face barriers to participation despite outreach mandates.
Large academic medical centers (e.g., UW Medicine, WSU Health Sciences) are well-positioned to lead multi-year, high-value grants due to existing infrastructure and research capacity. Smaller community hospitals and clinics may benefit from sub-awards or partnerships but could be excluded if they lack grant-writing support or compliance staff.
For-profit life sciences firms—especially those with existing commercial pipelines—will benefit from the commercialization focus and revenue-recapture clauses. However, small biotech startups or early-stage ventures may struggle to meet the “leverage additional funding” or “royalty recapture” requirements without legal/financial support.
State taxpayers benefit from a leveraged investment—$10M in tobacco taxes could unlock $20M+ in total funding. However, tobacco tax revenues are regressive, disproportionately burdening low-income smokers, and the private-account structure reduces legislative oversight over how those funds are used.
Private donors and foundations gain influence through board nominations and direct involvement in grant decisions, but the bill does not require donor transparency or disclose how their input shapes research priorities—raising concerns about equitable access to influence.